Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
复制标题
XRCC1基因多态性与肺癌患者临床结局相关性的荟萃分析
DOI:
10.1186/1471-2407-12-71
复制
发表时间:
2012-02-17
期刊:
影响因子:
3.8
通讯作者:
Zhou B
中科院分区:
文献类型:
--
作者:
Cui Z;Yin Z;Li X;Wu W;Guan P;Zhou B
BackgroundX-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) ofXRCC1are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs ofXRCC1(Arg194Trp, C > T, rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients.MethodsWe retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software.ResultsTwenty-two articles were included in the present analysis.XRCC1Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). ForXRCC1Arg399Gln, G/A genotype, A/A genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and A/A genotypes ofXRCC1Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23; 95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the patients carrying C/T+T/T genotype atXRCC1194 and G/G genotype atXRCC1399, the patients carrying 194 C/C and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response.ConclusionsGenetic polymorphisms inXRCC1gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients.
登录
查看更多内容
影响因子:
5.3
作者:
CALDECOTT, KW;MCKEOWN, CK;THOMPSON, LH
通讯作者:
THOMPSON, LH
影响因子:
5.3
作者:
Li, Mingchuan;Yin, Zhihua;Zhou, Baosen
通讯作者:
Zhou, Baosen
影响因子:
254.7
作者:
Parkin, DM;Bray, F;Pisani, P
通讯作者:
Pisani, P
影响因子:
4.7
作者:
Matullo, G;Palli, D;Vineis, P
通讯作者:
Vineis, P
DOI:
10.1016/j.mrgentox.2007.03.010
发表时间:
2007-07-28
影响因子:
1.9
作者:
De Ruyck, Kim;Szaumkessel, Marcin;Thierens, Hubert
通讯作者:
Thierens, Hubert